Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcellx Inc ACLX

Healthcare Biotechnology
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or... see more

Recent & Breaking News (NDAQ:ACLX)

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Business Wire November 7, 2024

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Business Wire November 5, 2024

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Business Wire August 8, 2024

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Business Wire May 9, 2024

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Business Wire May 9, 2024

Arcellx Provides First Quarter 2024 Financial Results

Business Wire May 9, 2024

Arcellx to Participate in Two Upcoming Investor Conferences

Business Wire May 7, 2024

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 4, 2024

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Business Wire March 20, 2024

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

PR Newswire February 29, 2024

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

PR Newswire February 28, 2024

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

PR Newswire December 8, 2023

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

PR Newswire November 15, 2023

Kite and Arcellx Announce Expansion in Strategic Partnership

Business Wire November 15, 2023

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

PR Newswire November 13, 2023

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

PR Newswire November 2, 2023

Arcellx to Participate in Two Upcoming Investor Conferences

PR Newswire October 26, 2023

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

PR Newswire August 14, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX

Newsfile July 23, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX

PR Newswire July 17, 2023